Meeting Overview - The second meeting of the second supervisory board of the company was held on June 9, 2025, with all three supervisors present [2][3]. Resolution Summary - The supervisory board approved the proposal to transfer 100% equity of its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., to Guangxi Drug Research Institute Co., Ltd. for a price of 15 million yuan [4][10]. - The board concluded that the transaction would enhance asset operation efficiency and is in line with the company's actual situation, with no harm to shareholders' interests [4][10]. Transaction Details - The transaction does not constitute a related party transaction or a major asset restructuring as defined by regulations, and there are no significant legal obstacles to its implementation [8][10]. - The transfer price of 15 million yuan was agreed upon based on voluntary and fair negotiations [14]. Subsidiary Overview - Shenzhen Tong'an Pharmaceutical has not conducted actual business in recent years and primarily holds approval numbers for 20 pharmaceutical products [13]. - The subsidiary's ownership is clear, with no encumbrances or legal issues affecting the transfer [13]. Financial Impact - The sale of the subsidiary is expected to increase the company's profit and cash flow in 2025, aligning with the company's strategic focus on the biopharmaceutical sector [21].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第二十一 次会议于 2025 年 6 月 9 日以现场的方式召开。会议通知已于 2025 年 6 月 6 日发 出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、监事会会议审议情况 证券代码：688136 证券简称：科兴制药 公告编号：2025-034 科兴生物制药股份有限公司 第二届监事会第二十一次会议决议公告 科兴生物制药股份有限公司监事会 2025 年 6 月 11 日 （一）审议通过《关于转让全资子公司股权的议案》 公司监事会认为：考虑到公司全资子公司深圳同安医药有限公司（以下简称 "同安医药"）近年来未实际开展业务，将公司持有的同安医药 100%的股权作 价 1,500 万元转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研 所"），有助于提高资产运营效率，符合公司的实际情况。本次交易 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-035 科兴生物制药股份有限公司 关于转让全资子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）拟将持有 的全资子公司深圳同安医药有限公司（以下简称"同安医药"或"标的公司"）100% 的股权转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研所"）， 转让价格为1,500.00万元。 本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组，且交易实施不存在重大法律障碍。 本次交易已经公司第二届董事会第二十五次会议审议通过，无需提交股 东大会审议。 一、交易概述 广西药研所由广西恒拓医药投资集团有限公司（以下简称"恒拓医药"）与南 宁高新工业企业发展投资基金中心（有限合伙）（以下简称"南宁高新基金"）共 同出资设立。恒拓医药是一家以药品研发、生产与销售为主的集团公司，2024 年收入规模达 5.34 亿元，总资产约 7.83 亿元；南宁 ...

Key Points - The core viewpoint of the articles highlights various corporate activities including project investments, sales data, stock acquisitions, share buybacks, and shareholding changes across multiple companies in different sectors. Company Activities - Co-creation Turf has a low proportion of domestic sports turf in its main business revenue [1] - Zhongcai Technology plans to invest in a manufacturing base for 110 sets of 100-meter wind turbine blades annually [1][2] - Huakang Clean has won a contract for the construction and equipment procurement of the first phase of the Chongqing 13th People's Hospital [1][2] - Jindi Group achieved a cumulative signed amount of 14.05 billion yuan from January to May [1][2] - Leidi Ke intends to acquire 51% of Yuzhan Precision, entering the embodied intelligence field [1][2] - Youfa Group has completed a share buyback, repurchasing 1.79% of its shares [1][3] - Jindun Co. plans to reduce its shareholding by up to 2% [1][3] - Caida Securities' shareholder Guokong Operations intends to reduce its stake by up to 3% [1][3] - Batong Energy plans to raise no more than 385 million yuan through a private placement to its controlling shareholder [1][3] - Founder Technology aims to raise no more than 1.98 billion yuan for an AI and high-density interconnect circuit board project [1][4]

Group 1 - Zhongtai Securities' controlling shareholder plans to increase its stake in the company by 300 million to 500 million yuan within three months, representing up to 0.76% of the total share capital [2] - Fangzheng Technology intends to raise no more than 1.98 billion yuan through a private placement, with the controlling shareholder participating in the subscription [4] - Kexing Pharmaceutical plans to transfer 100% equity of its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., to Guangxi Zhuang Autonomous Region Drug Research Institute, with no significant legal obstacles [2] Group 2 - Deep Kangjia A has decided to terminate the acquisition of 78% equity in Hongjing Microelectronics due to disagreements on core terms with the counterparty [6] - Haimer Technology is planning a change in company control, with stock suspension continuing for up to three trading days [7] - Dongfang Electric Heat has signed a strategic cooperation agreement with Shanghai Zhishi to develop electronic skin for robots [8] Group 3 - Redik plans to acquire 51% equity in Chengzhan Precision Technology Co., Ltd. for a total consideration of 104 million yuan, aiming to enter the embodied intelligence field [9] - Vanke A sold 22 million A-shares on June 10, raising approximately 146 million yuan, accounting for 0.18% of the total share capital [10] - Jintai Technology has not yet engaged in any business related to stablecoin concepts, despite recent market interest [11] Group 4 - Apac Co., Ltd. received a project designation from a large domestic automotive group, with an expected total sales amount of approximately 360 million yuan over a six-year lifecycle [12] - Ice Wheel Environment won two large cold chain projects with a total bid price exceeding 190 million yuan, representing about 2.9% of the company's projected revenue for 2024 [13] - Songyuan Safety received a project designation from a well-known domestic automotive manufacturer, totaling approximately 45 million yuan [14]

Group 1 - Vanke A announced the sale of 22 million A-share treasury stocks for a total of 146 million yuan, representing 0.18% of the company's total share capital, aimed at supplementing liquidity without impacting current profits [1] - Tencent Music plans to acquire 100% of Himalaya for a total consideration of $1.26 billion, which includes cash and shares, to expand its audio content ecosystem [1] - Dongfang Electric Heat signed a strategic cooperation agreement with Xiaomi's subsidiary to develop robotic electronic skin, focusing on flexible fabric pressure sensing applications [3] Group 2 - Chengdu Huamei launched a 4-channel, 12-bit, 16G high-precision RF direct sampling ADC chip, marking a significant breakthrough in high-speed data conversion technology [4] - Jinshi Technology clarified that it has not engaged in any business related to stablecoins, despite recent market interest, and noted a significant stock price increase of 76.51% over six trading days [5] - Xiantan Co. reported a 14.22% year-on-year increase in chicken product sales revenue for May, amounting to 469 million yuan [7]

证券代码：688136 证券简称：科兴制药 公告编号：2025-035 科兴生物制药股份有限公司 关于转让全资子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）拟将持有 的全资子公司深圳同安医药有限公司（以下简称"同安医药"或"标的公司"）100% 的股权转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研所"）， 转让价格为1,500.00万元。 本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组，且交易实施不存在重大法律障碍。 本次交易已经公司第二届董事会第二十五次会议审议通过，无需提交股 东大会审议。 一、交易概述 根据公司的整体经营规划，为进一步聚焦生物医药主赛道，降低管理成本， 提高资产运营效率，公司于2025年6月9日召开第二届董事会第二十五次会议、第 二届监事会第二十一次会议审议通过《关于转让全资子公司股权的议案》，公司 拟将持有的全资子公司同安医药100%的股权转让给广西药研所。 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-034 科兴生物制药股份有限公司 第二届监事会第二十一次会议决议公告 2025 年 6 月 11 日 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第二十一 次会议于 2025 年 6 月 9 日以现场的方式召开。会议通知已于 2025 年 6 月 6 日发 出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、监事会会议审议情况 （一）审议通过《关于转让全资子公司股权的议案》 公司监事会认为：考虑到公司全资子公司深圳同安医药有限公司（以下简称 "同安医药"）近年来未实际开展业务，将公司持有的同安医药 100%的股权作 价 1,500 万元转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研 所"），有助于提高资产运营效率，符合公司的实际情况。本次交易定价合理， 审议程序合规，不存在损害股东尤其是中小股东利益的情况。同意公司本次将同 安医药 100%股权转让给广西药研所的事项。 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 科 ...

Core Viewpoint - The animal vaccine sector has shown a positive performance with a 1.29% increase, ranking 10th among concept sectors, driven by significant gains in stocks like *ST Xianfeng, Kexing Pharmaceutical, and Jinhai Biological [1][2]. Group 1: Sector Performance - As of June 10, the animal vaccine concept saw 16 stocks rise, with *ST Xianfeng hitting the daily limit, while Kexing Pharmaceutical and Jinhai Biological increased by 6.40% and 4.72% respectively [1]. - The sector's performance is part of a broader market trend, with various other concepts also experiencing fluctuations, such as the transgenic sector rising by 3.15% [2]. Group 2: Capital Flow - The animal vaccine sector attracted a net inflow of 150 million yuan, with 10 stocks receiving significant capital inflows, and 7 stocks exceeding 10 million yuan in net inflow [2]. - Jinhai Biological led the net inflow with 67.34 million yuan, followed by Kexing Pharmaceutical and Dabeinong with 36.46 million yuan and 21.42 million yuan respectively [2][3]. Group 3: Stock-Specific Data - The top stocks by net capital inflow ratio included *ST Xianfeng at 10.73%, Kexing Pharmaceutical at 9.86%, and Jinhai Biological at 8.93% [3]. - The trading volume and turnover rates for key stocks indicate active trading, with Jinhai Biological showing a turnover rate of 15.46% and Kexing Pharmaceutical at 3.35% [3].

Core Insights - The recombinant protein sector saw a rise of 1.42%, ranking 8th among concept sectors, with 26 stocks increasing in value, including Sai Sheng Pharmaceutical which hit a 20% limit up [1] - Major gainers in the sector included Jie Ya Co., Yi Pin Hong, and Zhong Yuan He He, with increases of 14.83%, 9.40%, and 6.85% respectively [1] - The sector experienced a net outflow of 223 million yuan in capital, with 13 stocks receiving net inflows, and 10 stocks exceeding 10 million yuan in net inflows [2] Stock Performance - Sai Sheng Pharmaceutical led the net inflow with 165 million yuan, followed by Zhong Yuan He He, Ke Xing Pharmaceutical, and Yi Pin Hong with net inflows of 62.43 million yuan, 36.45 million yuan, and 28.04 million yuan respectively [2][3] - The top stocks by net inflow ratio included Sai Sheng Pharmaceutical at 23.69%, *ST Su Wu at 11.75%, and Ke Xing Pharmaceutical at 9.86% [3] Market Trends - The recombinant protein sector's performance was contrasted by other sectors, with the transgenic sector leading with a 3.15% increase, while EDR concept saw a decline of 2.63% [2] - The overall market sentiment reflected a mixed performance across various sectors, indicating selective investor interest [2]